Selected research
Industry Growth & Trends
Global VEGF Inhibitor Drugs Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global VEGF Inhibitor Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for VEGF Inhibitor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for VEGF Inhibitor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for VEGF Inhibitor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the VEGF Inhibitor Drugs market include Sanofi, Novartis AG, Merck & Co., Inc., Eli Lilly & Company, Pfizer, GlaxoSmithKline plc, Bayer AG, Genentech, Inc. (Roche) and Bristol-Myers-Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global VEGF Inhibitor Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The VEGF Inhibitor Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global VEGF Inhibitor Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to VEGF Inhibitor Drugs.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global VEGF Inhibitor Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
VEGF Inhibitor Drugs Market by Company
Sanofi
Novartis AG
Merck & Co., Inc.
Eli Lilly & Company
Pfizer
GlaxoSmithKline plc
Bayer AG
Genentech, Inc. (Roche)
Bristol-Myers-Squibb Company
AstraZeneca plc
VEGF Inhibitor Drugs Segment by Type
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
VEGF Inhibitor Drugs Segment by Application
Oncology
Ophthalmology
Others
VEGF Inhibitor Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global VEGF Inhibitor Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of VEGF Inhibitor Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of VEGF Inhibitor Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of VEGF Inhibitor Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Tyrosine Kinase Inhibitors
- Monoclonal Antibodies
- Others
Applications
- Oncology
- Ophthalmology
- Others
Companies covered
- Sanofi
- Novartis AG
- Merck & Co., Inc.
- Eli Lilly & Company
- Pfizer
- GlaxoSmithKline plc
- Bayer AG
- Genentech, Inc. (Roche)
- Bristol-Myers-Squibb Company
- AstraZeneca plc
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global VEGF Inhibitor Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global VEGF Inhibitor Drugs Market Size by Region (2021-2032)
- 1.4.1 Global VEGF Inhibitor Drugs Market Size by Region (2021-2026)
- 1.4.2 Global VEGF Inhibitor Drugs Market Size by Region (2027-2032)
- 1.5 Key Regions VEGF Inhibitor Drugs Market Size (2021-2032)
- 1.5.1 North America VEGF Inhibitor Drugs Market Size Growth Rate (2021-2032)
- 1.5.2 Europe VEGF Inhibitor Drugs Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific VEGF Inhibitor Drugs Market Size Growth Rate (2021-2032)
- 1.5.4 South America VEGF Inhibitor Drugs Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa VEGF Inhibitor Drugs Market Size Growth Rate (2021-2032)
2 VEGF Inhibitor Drugs Market by Type
- 2.1 Type Introduction
- 2.1.1 Tyrosine Kinase Inhibitors
- 2.1.2 Monoclonal Antibodies
- 2.1.3 Others
- 2.2 Global VEGF Inhibitor Drugs Market Size by Type
- 2.2.1 Global VEGF Inhibitor Drugs Market Size Overview by Type (2021-2032)
- 2.2.2 Global VEGF Inhibitor Drugs Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global VEGF Inhibitor Drugs Market Size Forecasted by Type (2027-2032)
- 2.3 Global VEGF Inhibitor Drugs Market Size by Regions
- 2.3.1 North America VEGF Inhibitor Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe VEGF Inhibitor Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific VEGF Inhibitor Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America VEGF Inhibitor Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa VEGF Inhibitor Drugs Market Size Breakdown by Type (2021-2026)
3 VEGF Inhibitor Drugs Market by Application
- 3.1 Type Introduction
- 3.1.1 Oncology
- 3.1.2 Ophthalmology
- 3.1.3 Others
- 3.2 Global VEGF Inhibitor Drugs Market Size by Application
- 3.2.1 Global VEGF Inhibitor Drugs Market Size Overview by Application (2021-2032)
- 3.2.2 Global VEGF Inhibitor Drugs Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global VEGF Inhibitor Drugs Market Size Forecasted by Application (2027-2032)
- 3.3 Global VEGF Inhibitor Drugs Market Size by Regions
- 3.3.1 North America VEGF Inhibitor Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe VEGF Inhibitor Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific VEGF Inhibitor Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America VEGF Inhibitor Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa VEGF Inhibitor Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 VEGF Inhibitor Drugs Industry Trends
- 4.2 VEGF Inhibitor Drugs Industry Drivers
- 4.3 VEGF Inhibitor Drugs Industry Opportunities and Challenges
- 4.4 VEGF Inhibitor Drugs Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by VEGF Inhibitor Drugs Revenue (2021-2026)
- 5.2 Global VEGF Inhibitor Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global VEGF Inhibitor Drugs Key Company Headquarters & Area Served
- 5.4 Global VEGF Inhibitor Drugs Company, Product Type & Application
- 5.5 Global VEGF Inhibitor Drugs Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global VEGF Inhibitor Drugs Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 VEGF Inhibitor Drugs Players Market Share by Revenue in 2025
- 5.6.3 2025 VEGF Inhibitor Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Sanofi
- 6.1.1 Sanofi Company Information
- 6.1.2 Sanofi Business Overview
- 6.1.3 Sanofi VEGF Inhibitor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Sanofi VEGF Inhibitor Drugs Product Portfolio
- 6.1.5 Sanofi Recent Developments
- 6.2 Novartis AG
- 6.2.1 Novartis AG Company Information
- 6.2.2 Novartis AG Business Overview
- 6.2.3 Novartis AG VEGF Inhibitor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Novartis AG VEGF Inhibitor Drugs Product Portfolio
- 6.2.5 Novartis AG Recent Developments
- 6.3 Merck & Co., Inc.
- 6.3.1 Merck & Co., Inc. Company Information
- 6.3.2 Merck & Co., Inc. Business Overview
- 6.3.3 Merck & Co., Inc. VEGF Inhibitor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Merck & Co., Inc. VEGF Inhibitor Drugs Product Portfolio
- 6.3.5 Merck & Co., Inc. Recent Developments
- 6.4 Eli Lilly & Company
- 6.4.1 Eli Lilly & Company Company Information
- 6.4.2 Eli Lilly & Company Business Overview
- 6.4.3 Eli Lilly & Company VEGF Inhibitor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Eli Lilly & Company VEGF Inhibitor Drugs Product Portfolio
- 6.4.5 Eli Lilly & Company Recent Developments
- 6.5 Pfizer
- 6.5.1 Pfizer Company Information
- 6.5.2 Pfizer Business Overview
- 6.5.3 Pfizer VEGF Inhibitor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Pfizer VEGF Inhibitor Drugs Product Portfolio
- 6.5.5 Pfizer Recent Developments
- 6.6 GlaxoSmithKline plc
- 6.6.1 GlaxoSmithKline plc Company Information
- 6.6.2 GlaxoSmithKline plc Business Overview
- 6.6.3 GlaxoSmithKline plc VEGF Inhibitor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 GlaxoSmithKline plc VEGF Inhibitor Drugs Product Portfolio
- 6.6.5 GlaxoSmithKline plc Recent Developments
- 6.7 Bayer AG
- 6.7.1 Bayer AG Company Information
- 6.7.2 Bayer AG Business Overview
- 6.7.3 Bayer AG VEGF Inhibitor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Bayer AG VEGF Inhibitor Drugs Product Portfolio
- 6.7.5 Bayer AG Recent Developments
- 6.8 Genentech, Inc. (Roche)
- 6.8.1 Genentech, Inc. (Roche) Company Information
- 6.8.2 Genentech, Inc. (Roche) Business Overview
- 6.8.3 Genentech, Inc. (Roche) VEGF Inhibitor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Genentech, Inc. (Roche) VEGF Inhibitor Drugs Product Portfolio
- 6.8.5 Genentech, Inc. (Roche) Recent Developments
- 6.9 Bristol-Myers-Squibb Company
- 6.9.1 Bristol-Myers-Squibb Company Company Information
- 6.9.2 Bristol-Myers-Squibb Company Business Overview
- 6.9.3 Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Product Portfolio
- 6.9.5 Bristol-Myers-Squibb Company Recent Developments
- 6.10 AstraZeneca plc
- 6.10.1 AstraZeneca plc Company Information
- 6.10.2 AstraZeneca plc Business Overview
- 6.10.3 AstraZeneca plc VEGF Inhibitor Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 AstraZeneca plc VEGF Inhibitor Drugs Product Portfolio
- 6.10.5 AstraZeneca plc Recent Developments
7 North America
- 7.1 North America VEGF Inhibitor Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America VEGF Inhibitor Drugs Market Size by Country (2021-2026)
- 7.3 North America VEGF Inhibitor Drugs Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe VEGF Inhibitor Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe VEGF Inhibitor Drugs Market Size by Country (2021-2026)
- 8.3 Europe VEGF Inhibitor Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific VEGF Inhibitor Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific VEGF Inhibitor Drugs Market Size by Country (2021-2026)
- 9.3 Asia-Pacific VEGF Inhibitor Drugs Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America VEGF Inhibitor Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America VEGF Inhibitor Drugs Market Size by Country (2021-2026)
- 10.3 South America VEGF Inhibitor Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa VEGF Inhibitor Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa VEGF Inhibitor Drugs Market Size by Country (2021-2026)
- 11.3 Middle East & Africa VEGF Inhibitor Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst